MeMed Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 100

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $12M

  • Investors
  • 24

MeMed General Information

Description

Developer of immuno-personalized diagnosis devices designed to detect bacterial and viral infections. The company's devices distinguish between bacterial and viral infections based on patients' immune responses to different infection types, enabling physicians to get rapid and actionable clinical information that guides them to make informed antibiotic treatment decisions.

Contact Information

Website
www.me-med.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 7 Nahum Het Street
  • Park High-Tech North
  • Tirat Carmel 3508506
  • Israel
+972
Primary Industry
Diagnostic Equipment
Other Industries
Other Healthcare Services
Corporate Office
  • 7 Nahum Het Street
  • Park High-Tech North
  • Tirat Carmel 3508506
  • Israel
+972

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

MeMed Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
12. Grant 12-Jan-2026 $12M Completed Generating Revenue
11. Later Stage VC (Series E) 01-Jul-2021 Completed Generating Revenue
10. Grant 13-Nov-2019 Completed Generating Revenue
9. Later Stage VC (Series D) 01-Jul-2018 Completed Generating Revenue
8. Grant 01-Sep-2017 Completed Generating Revenue
7. Debt - General Completed Generating Revenue
6. Grant 08-Sep-2016 Completed Generating Revenue
5. Grant 23-Jul-2015 Completed Generating Revenue
4. Later Stage VC (Series B) 01-Jan-2015 $23.8M $32.5M Completed Generating Revenue
3. Grant 14-Nov-2013 $8.15M $8.67M Completed Startup
To view MeMed’s complete valuation and funding history, request access »

MeMed Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Preferred D
Preferred C
Preferred B2
Preferred B1
Preferred A2 407,790 $0.010000 $4.95 $4.95 1x $4.95 14.46%
Preferred A1 145,800 $0.010000 $2.4 $2.4 1x $2.4 5.17%
To view MeMed’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

MeMed Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of immuno-personalized diagnosis devices designed to detect bacterial and viral infections. The company's devi
Diagnostic Equipment
Tirat Carmel, Israel
100 As of 2026

Mechelen, Belgium
 

Salt Lake City, UT
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

MeMed Competitors (2)

One of MeMed’s 2 competitors is Biocartis, a Venture Capital-Backed company based in Mechelen, Belgium.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Biocartis Venture Capital-Backed Mechelen, Belgium
BioFire Venture Capital-Backed Salt Lake City, UT
You’re viewing 2 of 2 competitors. Get the full list »

MeMed Patents

MeMed Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026069328-A1 Markers for diagnosing infections Pending 26-Sep-2024
WO-2026069329-A1 Markers for predicting severity Pending 26-Sep-2024
EP-4558829-A1 Markers for diagnosing infections Pending 20-Jul-2022
EP-4558829-A4 Markers for diagnosing infections Pending 20-Jul-2022
US-20260029409-A1 Markers for diagnosing infections Pending 20-Jul-2022 G01N33/6893
To view MeMed’s complete patent history, request access »

MeMed Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

MeMed Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds
Innovation Authority Government
Frog Design Venture Capital Minority
La Maison Partners Venture Capital Minority
Ping An Voyager Partners Venture Capital Minority
Poalim Equity PE/Buyout Minority
You’re viewing 5 of 24 investors. Get the full list »

MeMed FAQs

  • When was MeMed founded?

    MeMed was founded in 2009.

  • Where is MeMed headquartered?

    MeMed is headquartered in Tirat Carmel, Israel.

  • What is the size of MeMed?

    MeMed has 100 total employees.

  • What industry is MeMed in?

    MeMed’s primary industry is Diagnostic Equipment.

  • Is MeMed a private or public company?

    MeMed is a Private company.

  • What is MeMed’s current revenue?

    The current revenue for MeMed is .

  • How much funding has MeMed raised over time?

    MeMed has raised $195M.

  • Who are MeMed’s investors?

    Innovation Authority, Frog Design, La Maison Partners, Ping An Voyager Partners, and Poalim Equity are 5 of 24 investors who have invested in MeMed.

  • Who are MeMed’s competitors?

    Biocartis and BioFire are competitors of MeMed.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process